Merck KGaA (OTCMKTS:MKKGY) Sets New 52-Week High – What’s Next?

Merck KGaA (OTCMKTS:MKKGY)’s share price reached a new 52-week high on Thursday . The company traded as high as $33.8620 and last traded at $33.82, with a volume of 7749 shares. The stock had previously closed at $32.96.

Analysts Set New Price Targets

MKKGY has been the subject of a number of analyst reports. Sanford C. Bernstein raised shares of Merck KGaA to a “hold” rating in a report on Thursday, March 19th. Jefferies Financial Group initiated coverage on Merck KGaA in a research note on Tuesday, May 26th. They set a “hold” rating on the stock. Five research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the stock presently has a consensus rating of “Hold”.

Merck KGaA Price Performance

The company has a quick ratio of 1.00, a current ratio of 1.51 and a debt-to-equity ratio of 0.36. The firm’s 50 day simple moving average is $29.51 and its 200 day simple moving average is $28.56. The company has a market capitalization of $21.78 billion, a PE ratio of 14.98, a price-to-earnings-growth ratio of 2.95 and a beta of 0.99.

Merck KGaA (OTCMKTS:MKKGY) last announced its earnings results on Wednesday, May 13th. The company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.14. Merck KGaA had a net margin of 12.07% and a return on equity of 8.79%. The business had revenue of $6.03 billion for the quarter, compared to the consensus estimate of $5.93 billion. As a group, research analysts anticipate that Merck KGaA will post 1.87 EPS for the current fiscal year.

Merck KGaA Company Profile

Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.

Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility.